McKesson (NYSE:MCK) EVP Francisco Fraga Sells 650 Shares of Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 650 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00. Following the completion of the transaction, the executive vice president owned 4,414 shares of the company’s stock, valued at $4,868,465.44. This trade represents a 12.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francisco Fraga also recently made the following trade(s):

• On Wednesday, November 4th, Francisco Fraga sold 600 shares of McKesson stock. The shares were sold at an average price of $1,050.00, for a total transaction of $630,000.00.
• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The shares were sold at an average price of $995.80, for a total value of $796,640.00.

McKesson Stock Performance

Shares of McKesson stock opened at $1,060.79 on Friday. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,121.50. The company has a market capitalization of $123.68 billion, a P/E ratio of 27.28, a PEG ratio of 1.99 and a beta of 0.27. The company’s fifty day moving average is $938.13 and its two-hundred day moving average is $868.12.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. The business had revenue of $110.96 billion during the quarter, compared to the consensus estimate of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.86 earnings per share. As a group, equities analysts expect that McKesson Corporation will post 45.26 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 9.67%.

Hedge Funds Weigh In On McKesson

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nvwm LLC raised its position in McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 28 shares during the period. Delos Wealth Advisors LLC bought a new stake in McKesson during the second quarter worth about $27,000. Trellis Wealth Advisors LLC purchased a new stake in shares of McKesson during the third quarter valued at approximately $32,000. GK Wealth Management LLC bought a new position in McKesson during the third quarter valued at approximately $38,000. Finally, Curry Webb Wealth Management LLC purchased a new position in shares of McKesson during the 3rd quarter worth $38,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Analysts Set New Price Targets

Several research analysts have issued reports on MCK shares. Royal Bank Of Canada increased their price objective on McKesson from $845.00 to $965.00 and gave the stock a “sector perform” rating in a research note on Thursday. UBS Group raised their target price on shares of McKesson from $1,200.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday. Morgan Stanley set a $977.00 price target on shares of McKesson in a report on Tuesday, October 6th. Wells Fargo & Company boosted their price target on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, McKesson currently has an average rating of “Moderate Buy” and an average price target of $1,026.18.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.